Impact Factor: 4.1

Veröffentlicht seit 1. April 1987

Reviews in the Neurosciences

ISSN: 2191-0200

Editor-in-Chief: Joseph P. Huston

Wissenschaftlicher Beirat: Bianca Topic, Hojjat Adeli, Gyorgy Buzsaki, Jacqueline Crawley, Tim Crow, Paul Gold, Florian Holsboer, Carsten Korth, Jay-Shake Li, Gert Lubec, Bruce McEwen, Weihong Pan, Mikhail Pletnikov, Trevor Robbins, Alfons Schnitzler, Oswald Steward

Manuskript einreichen

Über diese Zeitschrift

Reviews in the Neurosciences provides a forum for reviews, critical evaluations and theoretical treatment of selective topics in the neurosciences. The journal is meant to provide an authoritative reference work for those interested in the structure and functions of the nervous system at all levels of analysis, including the genetic, molecular, cellular, behavioral, cognitive and clinical neurosciences. Contributions should contain a critical appraisal of specific areas and not simply a compilation of published articles.

Previously published by Freund Publishing House Ltd.

Topics

• Neurology
• Psychiatry
• Neuropharmacology
• Neurochemistry
• Neurophysiology
• Behavioral Psychology
• Pharmacology
• Neuroanatomy

Article formats

Reviews

Ihre Vorteile

Your Benefits

Rich publishing tradition since 1987
Critical approach to neurosciences
Comprehensive overview of all levels of analysis
Pioneering contributions bringing you up to date
Online publication ahead of print

Geschichte

Previously published by Freund Publishing House Ltd.

Other publications in the field

Abstracting und Indexing

Reviews in the Neurosciences ist in den folgenden Services indiziert:

AGRICOLA (National Agricultural Library)
Baidu Scholar
Cabells Journalytics
Chemical Abstracts Service (CAS) - CAplus
Chemical Abstracts Service (CAS) - SciFinder
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
EBSCO (relevant databases)
EBSCO Discovery Service
EMBASE
Genamics JournalSeek
Google Scholar
Japan Science and Technology Agency (JST)
J-Gate
Journal Citation Reports/Science Edition
JournalGuide
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
Medline
MyScienceWork
Naver Academic
Naviga (Softweco)
Norwegian Register for Scientific Journals, Series and Publishers
Pathway Studio
Primo Central (ExLibris)
ProQuest (relevant databases)
PsycINFO
PSYNDEX
Publons
PubMed
QOAM (Quality Open Access Market)
ReadCube
Reaxys
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
Text Mining
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - BIOSIS Previews
Web of Science - BIOSIS Reviews Reports and Meetings
Web of Science - Science Citation Index Expanded
WorldCat (OCLC)
X-MOL
Yewno Discover

Zusatzmaterial

Fachgebiete

Externe Links

Online Submission of Manuscripts

Band 34 Heft 6

August 2023

Öffentlich zugänglich 4. August 2023

Frontmatter

Seiten: i-iii

PDF downloaden

Öffentlich zugänglich 10. November 2022

An update to pain management after spinal cord injury: from pharmacology to circRNAs

Graciela L. Mazzone, María F. Coronel, Miranda Mladinic, Cynthia Sámano

Seiten: 599-611

Mehr PDF downloaden

Abstract

Neuropathic pain (NP) following a spinal cord injury (SCI) is often hard to control and therapies should be focused on the physical, psychological, behavioral, social, and environmental factors that may contribute to chronic sensory symptoms. Novel therapeutic treatments for NP management should be based on the combination of pharmacological and nonpharmacological options. Some of them are addressed in this review with a focus on mechanisms and novel treatments. Several reports demonstrated an aberrant expression of non-coding RNAs (ncRNAs) that may represent key regulatory factors with a crucial role in the pathophysiology of NP and as potential diagnostic biomarkers. This review analyses the latest evidence for cellular and molecular mechanisms associated with the role of circular RNAs (circRNAs) in the management of pain after SCI. Advantages in the use of circRNA are their stability (up to 48 h), and specificity as sponges of different miRNAs related to SCI and nerve injury. The present review discusses novel data about deregulated circRNAs (up or downregulated) that sponge miRNAs, and promote cellular and molecular interactions with mRNAs and proteins. This data support the concept that circRNAs could be considered as novel potential therapeutic targets for NP management especially after spinal cord injuries.

12. Dezember 2022

Current advances in stem cell therapy in the treatment of multiple sclerosis

Parnian Zolfaghari Baghbadorani, Amirmasoud Rayati Damavandi, Samira Moradi, Meysam Ahmadi, Peyman Bemani, Hamid Aria, Hossein Mottedayyen, Amirhossein Rayati Damavandi, Nahid Eskandari, Farshid Fathi

Seiten: 613-633

Mehr

Abstract

Multiple sclerosis (MS) is an inflammatory disease related to the central nervous system (CNS) with a significant global burden. In this illness, the immune system plays an essential role in its pathophysiology and progression. The currently available treatments are not recognized as curable options and, at best, might slow the progression of MS injuries to the CNS. However, stem cell treatment has provided a new avenue for treating MS. Stem cells may enhance CNS healing and regulate immunological responses. Likewise, stem cells can come from various sources, including adipose, neuronal, bone marrow, and embryonic tissues. Choosing the optimal cell source for stem cell therapy is still a difficult verdict. A type of stem cell known as mesenchymal stem cells (MSCs) is obtainable from different sources and has a strong immunomodulatory impact on the immune system. According to mounting data, the umbilical cord and adipose tissue may serve as appropriate sources for the isolation of MSCs. Human amniotic epithelial cells (hAECs), as novel stem cell sources with immune-regulatory effects, regenerative properties, and decreased antigenicity, can also be thought of as a new upcoming contender for MS treatment. Overall, the administration of stem cells in different sets of animal and clinical trials has shown immunomodulatory and neuroprotective results. Therefore, this review aims to discuss the different types of stem cells by focusing on MSCs and their mechanisms, which can be used to treat and improve the outcomes of MS disease.

2. Januar 2023

Targeting NMDA receptor signaling for therapeutic intervention in brain disorders

He Chen, Yuanping Dong, Yun Wu, Feng Yi

Seiten: 635-647

Mehr

Abstract

N -Methyl- d -aspartate (NMDA) receptor hyperfunction plays a key role in the pathological processes of depression and neurodegenerative diseases, whereas NMDA receptor hypofunction is implicated in schizophrenia. Considerable efforts have been made to target NMDA receptor function for the therapeutic intervention in those brain disorders. In this mini-review, we first discuss ion flux-dependent NMDA receptor signaling and ion flux-independent NMDA receptor signaling that result from structural rearrangement upon binding of endogenous agonists. Then, we review current strategies for exploring druggable targets of the NMDA receptor signaling and promising future directions, which are poised to result in new therapeutic agents for several brain disorders.

Öffentlich zugänglich 2. Februar 2023

A review of the application of three-dimensional convolutional neural networks for the diagnosis of Alzheimer’s disease using neuroimaging

Xinze Xu, Lan Lin, Shen Sun, Shuicai Wu

Seiten: 649-670

Mehr PDF downloaden

Abstract

Alzheimer’s disease (AD) is a degenerative disorder that leads to progressive, irreversible cognitive decline. To obtain an accurate and timely diagnosis and detect AD at an early stage, numerous approaches based on convolutional neural networks (CNNs) using neuroimaging data have been proposed. Because 3D CNNs can extract more spatial discrimination information than 2D CNNs, they have emerged as a promising research direction in the diagnosis of AD. The aim of this article is to present the current state of the art in the diagnosis of AD using 3D CNN models and neuroimaging modalities, focusing on the 3D CNN architectures and classification methods used, and to highlight potential future research topics. To give the reader a better overview of the content mentioned in this review, we briefly introduce the commonly used imaging datasets and the fundamentals of CNN architectures. Then we carefully analyzed the existing studies on AD diagnosis, which are divided into two levels according to their inputs: 3D subject-level CNNs and 3D patch-level CNNs, highlighting their contributions and significance in the field. In addition, this review discusses the key findings and challenges from the studies and highlights the lessons learned as a roadmap for future research. Finally, we summarize the paper by presenting some major findings, identifying open research challenges, and pointing out future research directions.

17. März 2023

A systematic review of the effects of transcranial photobiomodulation on brain activity in humans

Marjorie Dole, Vincent Auboiroux, Lilia Langar, John Mitrofanis

Seiten: 671-693

Mehr

Abstract

In recent years, transcranial photobiomodulation (tPBM) has been developing as a promising method to protect and repair brain tissues against damages. The aim of our systematic review is to examine the results available in the literature concerning the efficacy of tPBM in changing brain activity in humans, either in healthy individuals, or in patients with neurological diseases. Four databases were screened for references containing terms encompassing photobiomodulation, brain activity, brain imaging, and human. We also analysed the quality of the included studies using validated tools. Results in healthy subjects showed that even after a single session, tPBM can be effective in influencing brain activity. In particular, the different transcranial approaches – using a focal stimulation or helmet for global brain stimulation – seemed to act at both the vascular level by increasing regional cerebral blood flow (rCBF) and at the neural level by changing the activity of the neurons. In addition, studies also showed that even a focal stimulation was sufficient to induce a global change in functional connectivity across brain networks. Results in patients with neurological disease were sparser; nevertheless, they indicated that tPBM could improve rCBF and functional connectivity in several regions. Our systematic review also highlighted the heterogeneity in the methods and results generated, together with the need for more randomised controlled trials in patients with neurological diseases. In summary, tPBM could be a promising method to act on brain function, but more consistency is needed in order appreciate fully the underlying mechanisms and the precise outcomes.

20. April 2023

Microbiota–gut–brain axis and related therapeutics in Alzheimer’s disease: prospects for multitherapy and inflammation control

Jiahao Li, Feng Zhang, Li Zhao, Chunbo Dong

Seiten: 695-718

Mehr

Abstract

Alzheimer’s disease (AD) is the most common type of dementia in the elderly and causes neurodegeneration, leading to memory loss, behavioral disorder, and psychiatric impairment. One potential mechanism contributing to the pathogenesis of AD may be the imbalance in gut microbiota, local and systemic inflammation, and dysregulation of the microbiota–gut–brain axis (MGBA). Most of the AD drugs approved for clinical use today are symptomatic treatments that do not improve AD pathologic changes. As a result, researchers are exploring novel therapeutic modalities. Treatments involving the MGBA include antibiotics, probiotics, transplantation of fecal microbiota, botanical products, and others. However, single-treatment modalities are not as effective as expected, and a combination therapy is gaining momentum. The purpose of this review is to summarize recent advances in MGBA-related pathological mechanisms and treatment modalities in AD and to propose a new concept of combination therapy. “MGBA-based multitherapy” is an emerging view of treatment in which classic symptomatic treatments and MGBA-based therapeutic modalities are used in combination. Donepezil and memantine are two commonly used drugs in AD treatment. On the basis of the single/combined use of these two drugs, two/more additional drugs and treatment modalities that target the MGBA are chosen based on the characteristics of the patient’s condition as an adjuvant treatment, as well as the maintenance of good lifestyle habits. “MGBA-based multitherapy” offers new insights for the treatment of cognitive impairment in AD patients and is expected to show good therapeutic results.

Ahead-of-Print / Just-Accepted

Ahead-of-Print / Just-Accepted

Band 34 (2023)

Band 33 (2022)

Band 32 (2021)

Band 31 (2020)

Band 30 (2019)

Band 29 (2018)

Band 28 (2017)

Band 27 (2016)

Band 26 (2015)

Band 25 (2014)

Band 24 (2013)

Band 23 (2012)

Band 22 (2011)

Band 21 (2010)

Band 20 (2009)

Band 19 (2008)

Band 18 (2007)

Band 17 (2006)

Band 16 (2005)

Band 15 (2004)

Band 14 (2003)

Band 13 (2002)

Band 12 (2001)

Band 11 (2000)

Band 10 (1999)

Band 9 (1998)

Band 8 (1997)

Band 7 (1996)

Band 6 (1995)

Band 5 (1994)

Band 4 (1993)

Band 3 (1992)

Band 2 (1990)

Band 1 (1987)

Heft 3-4

Journal Impact Factor	4.1	2022, Journal Citation Reports (Clarivate, 2023)
5-year Journal Impact Factor	4.7	2022, Journal Citation Reports (Clarivate, 2023)
Journal Citation Indicator	0.94	2022, Journal Citation Reports (Clarivate, 2023)
CiteScore	8.1	2022, Scopus (Elsevier B.V., 2023)
SCImago Journal Rank	1.074	2022, SJR (Scimago Lab, 2023; Data Source: Scopus)
Source Normalized Impact per Paper	1.091	2022, CWTS Journal Indicators (CWTS B.V., 2023; Data Source: Scopus)

Weitere Informationen über Zeitschriftenmetriken

Einreichen

Submission

You can easily submit your manuscript online. Simply go to http://mc.manuscriptcentral.com/revneuro and you will be guided through the whole peer-reviewing and publishing process.

Your benefits of publishing with us

Easy-to-use online submission, peer review, and publication system
Short turnaround times
Free publication of color figures both in online and print editions
No page charges
High quality peer-review
Every article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing services
High Impact Factor (5 year: 3.358)
Secure archiving by De Gruyter and the independent archiving service Portico
Professional sales and marketing activities

Submission process

Online submission of your paper via our submission management tool following the Instructions for Authors (you will be guided through every step)
Peer review process with independent, external reviewers
Decision on your paper will be made within 3 weeks on average
If accepted: Publication online and in print – online ahead of print as well
Authors have the option to publish their paper Open Access (OA fee applies)

Please note

Before submitting your article please have a look at our Ethical Guidelines and our Copyright Transfer Agreement
Once your article is accepted you have the option to publish it open access
Our Repository Policy allows you to distribute 30 PDF copies of your published article to colleagues (the PDF has to include the information that it is an author's copy). Please also feel free to distribute the link to the online abstract
If you have any general questions please visit our FAQ for authors

We look forward to receiving your manuscript!

Hybrid Open Access

In this journal, authors have the option to publish their article under an open access license. Open Access allows you as an author to retain copyright and share your findings with colleagues and interested parties worldwide without any restraints.
Please note that authors from institutions with which we have a transformative agreement can publish open access without paying an article processing charge (APC). More information on the eligible institutions and articles can be found under the "Funding and Support" tab here.

Editorial

Editor-in-Chief

Joseph P. Huston (Düsseldorf, Germany)

Associate Editor

Bianca Topic (Düsseldorf, Germany)

Editorial Board

Hojjat Adeli (Columbus, USA)
Gyorgy Buzsaki (New York, USA)
Jacqueline N. Crawley (Bethesda, USA)
Tim J. Crow (Headington, UK)
Paul E. Gold (Champaign, USA)
Florian Holsboer (Munich, Germany)
Carsten Korth (Düsseldorf, Germany)
Jay-Shake Li (Chiayi, Taiwan)
Gerd Lubec (Vienna, Austria)
Claudia Mattern (Emmetten, Switzerland)
Bruce S. McEwen (New York, USA)
Weihong Pan (Baton Rouge, USA)
Mikhail Pletnikov (Baltimore, USA)
Trevor W. Robbins (Cambridge, UK)
Alfons Schnitzler (Düsseldorf, Germany)
Oswald Steward (Irvine, USA)

Editorial Office

de Gruyter
Genthiner Str. 13
D-10785 Berlin
Germany
Tel. 0049-30-26005176
Fax 0049-30-26005352
e-mail: rev.neurosci.editorial@degruyter.com

(English)

Online ISSN: 2191-0200
Print ISSN: 0334-1763
Typ: Zeitschrift
Sprache: Englisch
Verlag: De Gruyter
Erstveröffentlichung: 1. April 1987
Erscheinungsweise: 8 Hefte pro Jahr
Zielgruppe: Neuroscientists, Psychiatrists, Psychologists, Life Scientists, Pharmacologists, Biologists